Movement Alert｜LEADS BIOLABS-B Rises 5.11% in Regular Trading, Core Pipeline Cholangiocarcinoma Phase II Study Completes Full Patient Enrollment

Market Focus07-31

On July 31, LEADS BIOLABS-B rose 5.11% in regular trading, trading at HK$52.9/share, with turnover of HK$37.318 million.

On the news front, the company announced on July 30 that its core drug Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, has completed full enrollment of all 70 patients in its Phase II clinical study for first-line treatment of advanced biliary tract cancer. The study entered its expansion phase in April based on favorable safety data and better-than-expected efficacy results, and rapidly completed enrollment thereafter, demonstrating efficient clinical execution.

This milestone reinforces Opamtistomig's breakthrough potential in immunologically cold tumors. The drug had previously been granted Priority Review status by China's NMPA for extrapulmonary neuroendocrine carcinoma, formally locking in its commercialization timeline. If final results are positive, Opamtistomig could become the first PD-L1/4-1BB bispecific antibody approved globally for cholangiocarcinoma.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181232541?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 10:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181232541","market":"hk","top_or_hot":-1,"title":"Movement Alert｜LEADS BIOLABS-B Rises 5.11% in Regular Trading, Core Pipeline Cholangiocarcinoma Phase II Study Completes Full Patient Enrollment","media":"Market Focus","content":"<p><p>On July 31, LEADS BIOLABS-B rose 5.11% in regular trading, trading at HK$52.9/share, with turnover of HK$37.318 million.</p><p>On the news front, the company announced on July 30 that its core drug Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, has completed full enrollment of all 70 patients in its Phase II clinical study for first-line treatment of advanced biliary tract cancer. The study entered its expansion phase in April based on favorable safety data and better-than-expected efficacy results, and rapidly completed enrollment thereafter, demonstrating efficient clinical execution.</p><p>This milestone reinforces Opamtistomig's breakthrough potential in immunologically cold tumors. The drug had previously been granted Priority Review status by China's NMPA for extrapulmonary neuroendocrine carcinoma, formally locking in its commercialization timeline. If final results are positive, Opamtistomig could become the first PD-L1/4-1BB bispecific antibody approved globally for cholangiocarcinoma.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜LEADS BIOLABS-B Rises 5.11% in Regular Trading, Core Pipeline Cholangiocarcinoma Phase II Study Completes Full Patient Enrollment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜LEADS BIOLABS-B Rises 5.11% in Regular Trading, Core Pipeline Cholangiocarcinoma Phase II Study Completes Full Patient Enrollment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-31 10:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 31, LEADS BIOLABS-B rose 5.11% in regular trading, trading at HK$52.9/share, with turnover of HK$37.318 million.</p><p>On the news front, the company announced on July 30 that its core drug Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, has completed full enrollment of all 70 patients in its Phase II clinical study for first-line treatment of advanced biliary tract cancer. The study entered its expansion phase in April based on favorable safety data and better-than-expected efficacy results, and rapidly completed enrollment thereafter, demonstrating efficient clinical execution.</p><p>This milestone reinforces Opamtistomig's breakthrough potential in immunologically cold tumors. The drug had previously been granted Priority Review status by China's NMPA for extrapulmonary neuroendocrine carcinoma, formally locking in its commercialization timeline. If final results are positive, Opamtistomig could become the first PD-L1/4-1BB bispecific antibody approved globally for cholangiocarcinoma.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1181232541","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181232541","pubTimestamp":1785463394,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 31, LEADS BIOLABS-B rose 5.11% in regular trading, trading at HK$52.9/share, with turnover of HK$37.318 million.On the news front, the company announced on July 30 that its core drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B"},"translate_title":"走势提醒|LEADS BIOLABS-B常规交易涨5.11%，核心管线胆管癌II期研究完成全部患者入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"On July 31, LEADS BIOLABS-B rose 5.11% in regular trading, trading at HK$52.9/share, with turnover of HK$37.318 million.On the news front, the company announced on July 30 that its core drug Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, has completed full enrollment of all 70 patients in its Phase II clinical study for first-line treatment of advanced biliary tract cancer. The study entered its expansion phase in April based on favorable safety data and better-than-expected efficacy results, and rapidly completed enrollment thereafter, demonstrating efficient clinical execution.This milestone reinforces Opamtistomig's breakthrough potential in immunologically cold tumors. The drug had previously been granted Priority Review status by China's NMPA for extrapulmonary neuroendocrine carcinoma, formally locking in its commercialization timeline. If final results are positive, Opamtistomig could become the first PD-L1/4-1BB bispecific antibody approved globally for cholangiocarcinoma.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181232541","isCrawlerRequest":true}